Hotspot Therapeutics Inc. has identified diazepino-thieno-quinoxaline compounds acting as MAP kinase-activated protein kinase 2 (MAPKAPK2; MK2) inhibitors reported to be useful for the treatment of cancer, arthritis, asthma, psoriasis, inflammatory bowel disease, multiple sclerosis, myasthenia gravis and inflammatory disorders.

Simcere Zaiming Pharmaceutical Co. Ltd. has synthesized tricyclic compounds acting as ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.

Molecure SA has disclosed ubiquitin C-terminal hydrolase 7 (USP7; HAUSP) inhibitors reported to be useful for the treatment of cancer, infections, neurodegeneration, gastrointestinal, metabolic, immunological and cardiovascular disorders, as well as sexual function, breast and reproduction disorders, among others.

Iambic Therapeutics Inc. has described HER2 (erbB2) and HER2 (exon 20 insertion [Ex20Ins] [Ala775_Gly776insTyrValMetAla]) mutant inhibitors reported to be useful for the treatment of non-small-cell lung cancer (NSCLC).

Scientists at Foshan Ionova Biotherapeutics Co. Ltd., Guangdong Touchstone Translational Research Institute Co. Ltd. and Shenzhen Ionova Life Science Co. Ltd. have divulged prostaglandin E2 receptor EP4 subtype (PTGER4; EP4) antagonists reported to be useful for the treatment of cancer, inflammatory disorders and pain.

Shanghai Yingli Pharmaceutical Co. Ltd. has identified dual-acting phosphatidylinositol 3-kinase (PI3K) and histone deacetylase (HDAC) inhibitors reported to be useful for the treatment of cancer.

Sanofi SA has synthesized compounds acting as selective estrogen receptor degradation inducers (SERDs) reported to be useful for the treatment of cancer, endometriosis, osteoporosis, benign prostatic hyperplasia and inflammatory disorders.

Scientists at Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have disclosed poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.

Real life economics, not functionality, is the standard for determining a relevant antitrust market for distinct versions of a prescription drug, the U.S. Court of Appeals for the Second Circuit said as it schooled a lower court and handed Regeneron Pharmaceuticals Inc. a win in its ongoing litigation with Novartis AG and Vetter Pharma International GmbH over the prefilled syringe market for eye drugs Eylea (aflibercept) and Lucentis (ranibizumab).

Redx Pharma plc has described discoidin domain-containing receptor 1 (DDR1) and/or discoidin domain-containing receptor 2 (DDR2) inhibitors reported to be useful for the treatment of cardiovascular, renal, inflammatory disorders, liver diseases, fibrosis, transplant rejection and cancer.